Rimonabant
货号：
9000484-5mg 基本售价：
588.0 元 规格：
5 mg
产品信息
概述| 货号 | 9000484-5mg |
| 描述 | Rimonabant, also known as SR141716, was the first selective central cannabinoid (CB1) receptor inverse agonist (Ki = 1.8 nM) to be developed as an appetite suppressant, anti-obesity drug.1 It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios.2 However, rimonabant reportedly produces adverse psychiatric and neurological effects (e.g., depression or anxiety) and therefore is not approved by the FDA for use as a weight control medication.2 Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.3 |
| 别名 | SR141716; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Rinaldi-Carmona, M.,Barth, F.,Héaulme, M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350(2-3), 240-244 (1994).
2.Leite, C.E.,Mocelin, C.A.,Petersen, G.O., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacological Reports 61(2), 217-224 (2009).
3.Malfitano, A.M.,Laezza, C.,Pisanti, S., et al. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. British Journal of Pharmacology 153(5), 1003-1010 (2009).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 463.8 |
| 分子式 | C22H21Cl3N4O |
| CAS号 | 168273-06-1 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
